Cargando…

Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients

The impact of distinct disease‐modifying therapies (DMTs) on severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune‐responses in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trümpelmann, Susan, Schulte‐Mecklenbeck, Andreas, Steinberg, Olga V., Wirth, Timo, Fobker, Manfred, Lohmann, Lisa, Lünemann, Jan D., Wiendl, Heinz, Gross, Catharina C., Klotz, Luisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111759/ https://www.ncbi.nlm.nih.gov/pubmed/35213793 http://dx.doi.org/10.1111/cts.13256

Ejemplares similares

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study
por: Lohmann, Lisa, et al.
Publicado: (2018)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report
por: Lohmann, Lisa, et al.
Publicado: (2022)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Immune signatures of prodromal multiple sclerosis in monozygotic twins
por: Gerdes, Lisa Ann, et al.
Publicado: (2020)

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid
por: Grauer, Oliver M, et al.
Publicado: (2015)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound
por: Janoschka, Claudia, et al.
Publicado: (2022)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series
por: Strippel, Christine, et al.
Publicado: (2022)

Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer
por: Dik, Andre, et al.
Publicado: (2018)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Contactin-associated protein 2 autoantibodies can be associated with multifocal motor-like neuropathy: a case report
por: Müller-Miny, Louisa, et al.
Publicado: (2023)

MS-Versorgung heute und Vision für die Zukunft - eine Rolle für die ASV?
por: Korsukewitz, Catharina, et al.
Publicado: (2022)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System
por: Ruland, Tillmann, et al.
Publicado: (2018)

Genetic determinants of the humoral immune response in MS
por: Gasperi, Christiane, et al.
Publicado: (2020)

Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab
por: Strippel, Christine, et al.
Publicado: (2017)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Classification of neurological diseases using multi-dimensional CSF analysis
por: Gross, Catharina C, et al.
Publicado: (2021)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry
por: Heming, Michael, et al.
Publicado: (2023)

Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
por: Keller, Christian W., et al.
Publicado: (2021)

Gut–CNS-Axis as Possibility to Modulate Inflammatory Disease Activity—Implications for Multiple Sclerosis
por: Fleck, Ann-Katrin, et al.
Publicado: (2017)

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis
por: Schafflick, David, et al.
Publicado: (2020)

Humoral signatures of MOG-antibody-associated disease track with age and disease activity
por: Spatola, Marianna, et al.
Publicado: (2023)

Fingolimod treatment promotes regulatory phenotype and function of B cells
por: Grützke, Berit, et al.
Publicado: (2015)

Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses
por: Räuber, Saskia, et al.
Publicado: (2021)

Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments
por: Repple, Jonathan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bnlllh84368cp3q4d1is95amul